This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Instant replay! In case you missed it, here it is! CLL Society’s latest Webinar — “MRD: What Should It Mean to Me?” If you have ever dreamed of coming to a point where your CLL treatment could be paused or stopped (known as “limited duration”) please know that researchers such as Dr. Mato et al are focusing their attention on that very target. Testing for MRD (minimal or measurable residual disease) status, during or after treatment, may well become the new indicator determining when you can safely stop certain CLL treatments. In this August 14th CLL Society webinar, featured CLL expert Dr. Anthony Mato and moderator Dr. Brian Koffman addressed our viewers’ questions and brought us the latest information on MRD testing. At the CLL Society, it’s never too late! All CLL Society webinars are archived for your continued learning. Check out the recorded webinar here.
BTK inhibitors are getting plenty of attention in this week’s Alert!
During this ASH 2019 interview, Dr. Anthony Mato discusses data he presented on LOXO-305. This selective, reversible (non-covalent) BTK inhibitor offers the potential advantage of continuing to be able to block the BTK pathway even when it has mutated, leading to resistance to the approved BTK inhibitors ibrutinib and acalabrutinib.
To further the discussion on BTK inhibitors, we encourage you to view the archived Cancer Coach Live Webinar from August 10th: What You Need to Know about BTK Inhibitors as Treatment for Your/Your Loved One’s CLL
Improving physician-patient decision making for treatment of CLL with BTK inhibition featuring CLL expert Dr. Matthew Davids, Associate Professor of Medicine Harvard Medical School, Josie Montegaard, Nurse Practitioner, and CLL patient, frequent panelist and CLL Tribune contributor, Doreen Zetterlund promoting meaningful and productive dialog between patients and HCPs as relates to CLL treatment regimens incorporating BTK inhibitors. Watch the recorded webinar here.
Upcoming CURE Webinar
CLL Society’s Director of Support Groups, Terry Evans, joins panelists Dr. Erlene Seymour and Dr. Hun Ju Lee in CURE’s Educated Patient CLL Webinar on August 27, where discussion will focus on BTK inhibitors, oral vs infusion treatment options, shared decision-making, and other important topics to CLL patients and their caregivers. Learn more and register here.
Window of Opportunity! Funds Available for Out-of-Pocket Medication Costs for CLL Patients. The PAN Foundation helps federally and commercially insured people living with life-threatening, chronic, and rare diseases with out-of-pocket costs for their prescribed medications. Funds are currently available. Act now!Learn more and apply here.
Please Support the CLL Society, the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
The CLL Society is invested in your long life.
Please invest in the long life of the CLL Society by investing in our work.
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.